Animal Models of Depression; D. Refojo and J. M.
Neurophysiological and Neuropsychological Models of Depression; S. Moratti, A. Fernandez, and G. Rubio
Neural Foundations of Major Depression: Classical Approaches and New Frontiers; J. P. Hamilton, D. J. Furman, and I. H. Gotlib
Genetic Regulation of Emotion Brain Circuitries; U. Rabl, C. Scharinger, T. Hofmaier, M. Freissmuth, and L. Pezawas
Development of Brain Monoaminergic Systems; M. P. Smidt
Contribution of Pharmacology to Development of Monoaminergic Hypotheses of Depression; F. Lopez-Munoz and C. Alamo
Serotonergic Pathways in Depression; S. C. Altieri, Y. S. Singh, E. Sibille, and A. M. Andrews
Noradrenergic System in Depression; J. J. Meana, L. F. Callado, and J. A. Garcia-Sevilla
Glutamatergic System and Mood Disorders; R. Machado-Vieira and C. A. Zarate Jr.
Role of the Endocannabinoid System in Etiopathology of Major Depression; R. J. McLaughlin, F. Rodriguez Bambico, and G. Gobbi
Opioid System and Depression; C. Alba-Delgado, P. Sanchez-Blazquez, E. Berrocoso, J. Garzon, and J. A. Mico
Chronobiological Rhythms, Melatonergic System, and Depression; C. Alamo and F. Lopez-Munoz
Corticotropin-Releasing Factor and Hypothalamic-Pituitary-Adrenal Axis Regulation of Behavioral Stress Response and Depression; G. R. Valdez
Depression and Cytokine-Regulated Pathways; B. T. Baune
Tachykinins and Tachykinin Receptor Antagonists in Depression: Therapeutic Implications; T.-S. Lee and K. R. Krishnan
Role of Neuropeptide Y in Depression: Current Status; J. C. Morales-Medina and R. Quirion
Nitric Oxide Signaling in Depression and Antidepressant Action; G. Wegener and A. A. Mathe
Beta-Arrestins in Depression: A Molecular Switch from Signal Desensitization to Alternative Intracellular Adaptor Functions; S. Avissar and G. Schreiber
Brain-Derived Neurotrophic Factor and Major Depression; K. Sakata
Role of Cyclic Nucleotide Phosphodiesterases in Depression and Antidepressant Activity; Y. Xu, H.-T. Zhang, and J. M. O'Donnell
Vascular Depression: A Neuropsychological Perspective; B. T. Mast, B. P. Yochim, J. S. Carmasin, and S. V. Rowe
Neurobiological Basis for Development of New Antidepressant Agents; C. Alamo and F. Lopez-Munoz
Francisco Lopez-Munoz's main research areas are the postnatal development of mammals' pineal gland after chemical sympathectomy, the biological bases of drug abuse, psychiatric disorders and dual diagnosis. He also studies psychotropic drug interactions, the neurobiology of aggressivity, the bibliometric techniques applied to mental health-related disciplines and neuropsychopharmacology, the combination therapies with antidepressant and antipsychotic drugs and the history of the psychopharmacology. Dr. Lopez-Munoz is editor/author of 14 books and 137 chapters of books related to the psychopharmacology. Cecilio lamo's research focuses on the field of neuropsychopharmacology, especially in the area of antidepressants, antipsychotics and analgesics. He has supervised several doctoral theses addressing the pharmacological analysis of mechanisms of action and the tolerance of and dependence on morphine and other analgesics. He has studied the non-endocrinological properties of TRH as an analgesic and anticonvulsant and developed research into new analgesics and antidepressants with serotonergic activity, patenting two of them. He is presently conducting research in pharmacoeconomics, bibliometrics and neuropsychopharmacology. He has published over 70 papers, nearly two dozen books, 100 book chapters and more than 300 papers in Spanish scientific journals.